Battle of the algorithms.
Can a device control a patient’s blood sugar based on bodyweight alone?
Cracking the cancer code.
Wright's bone filler sales are growing fast, but Medtronic still rules.
It's a start, but sham-controlled trials are needed.
J&J sells another unit.
A trial success is in the bag, but are surrogate endpoints enough?